https://myfacesurgeon.com/trends Source-linked updates about facial aesthetics, surgery, injectables, skin and recovery, connected to relevant Dagan MD educational resources. en-US Tue, 28 Jul 2026 12:00:00 GMT https://myfacesurgeon.com/trends/trenibote-glabellar-lines-phase3-2026 https://myfacesurgeon.com/trends/trenibote-glabellar-lines-phase3-2026 Fri, 24 Jul 2026 12:00:00 GMT A placebo-controlled phase 3 study published July 24, 2026 found trenibotulinumtoxinE improved moderate-to-severe glabellar lines quickly, with effects observed at hour 8, peaking at day 7 and largely returning by day 21. The study is about rapid onset and short duration in a controlled setting, not proof that a shorter-acting toxin is the right fit for every forehead or frown-line plan. trenibotulinumtoxinE Tal Dagan, MD, FACS https://myfacesurgeon.com/compare/facelift-vs-neck-lift https://myfacesurgeon.com/compare/facelift-vs-neck-lift Fri, 24 Jul 2026 12:00:00 GMT This comparison exists because lower-face descent and neck laxity often appear together, yet a focused neck operation and a seamless facelift do not address the same anatomy. The useful question is not which operation is larger; it is which tissue layer and region are actually responsible for the change a patient sees. Decision comparison Tal Dagan, MD, FACS https://myfacesurgeon.com/compare/botox-vs-daxxify https://myfacesurgeon.com/compare/botox-vs-daxxify Fri, 24 Jul 2026 12:00:00 GMT This comparison exists because both products temporarily reduce selected muscle activity, yet their formulations, units and maintenance rhythms are not interchangeable. The decision should begin with the expression pattern and the value a patient places on flexibility versus a potentially longer studied interval. Product familiarity is not a substitute for checking contraindications, prior response and the exact region being treated. Decision comparison Tal Dagan, MD, FACS https://myfacesurgeon.com/compare/filler-vs-fat-transfer https://myfacesurgeon.com/compare/filler-vs-fat-transfer Fri, 24 Jul 2026 12:00:00 GMT This page exists because filler and fat transfer can both contribute volume, but they begin with different materials, different treatment settings and different kinds of uncertainty. Comparing them by syringe count alone misses donor-site planning, tissue behavior, reversibility and the scale of the correction. Decision comparison Tal Dagan, MD, FACS https://myfacesurgeon.com/compare/lip-lift-vs-lip-filler https://myfacesurgeon.com/compare/lip-lift-vs-lip-filler Fri, 24 Jul 2026 12:00:00 GMT This comparison exists because a lip can appear small for more than one reason. A long visible distance beneath the nose, limited pink-lip show and limited tooth show describe a position problem; a desire for shape or volume may describe a filler problem. Treating one as the other can distort proportion. The smile must remain central to planning. Decision comparison Tal Dagan, MD, FACS https://myfacesurgeon.com/compare/sculptra-vs-filler https://myfacesurgeon.com/compare/sculptra-vs-filler Fri, 24 Jul 2026 12:00:00 GMT This comparison exists because “injectable volume” can mean immediate gel support or a gradual collagen-stimulating plan. The treatments differ in material, pace, adjustability, suitable areas and how an early result should be interpreted. A temporary swollen appearance after injection should not be confused with mature collagen response or a settled gel contour. The consultation should also identify whether the concern is truly missing support, because neither material repositions substantially descended tissue or replaces a muscle-directed treatment. Decision comparison Tal Dagan, MD, FACS https://myfacesurgeon.com/compare/brow-lift-vs-eyelid-lift https://myfacesurgeon.com/compare/brow-lift-vs-eyelid-lift Fri, 24 Jul 2026 12:00:00 GMT This comparison exists because upper-face heaviness may begin at the brow, within the eyelid or at both levels. Removing eyelid skin when the brow is the main source, or lifting the brow when lid anatomy is the main issue, can answer the wrong question. Dry-eye health, hairline position and natural asymmetry also influence which recovery and scar tradeoffs are reasonable. The safest plan preserves eye function and recognizable expression. Decision comparison Tal Dagan, MD, FACS https://myfacesurgeon.com/compare/surgical-vs-nonsurgical-rejuvenation https://myfacesurgeon.com/compare/surgical-vs-nonsurgical-rejuvenation Fri, 24 Jul 2026 12:00:00 GMT This comparison exists because “facial rejuvenation” is not one diagnosis. Surgery, neuromodulators, fillers, biostimulators and skin treatments work at different anatomical levels. Choosing by downtime alone can lead to repeated treatment of the wrong layer. Decision comparison Tal Dagan, MD, FACS https://myfacesurgeon.com/guides/cost-of-facelift-nyc https://myfacesurgeon.com/guides/cost-of-facelift-nyc Fri, 24 Jul 2026 12:00:00 GMT What changes a New York facelift quotation, what the written quote should include, and why the final figure follows an examination rather than an online price range. Cost guide Tal Dagan, MD, FACS https://myfacesurgeon.com/guides/cost-of-rhinoplasty-nyc https://myfacesurgeon.com/guides/cost-of-rhinoplasty-nyc Fri, 24 Jul 2026 12:00:00 GMT The anatomical, functional, technical and setting-related factors that shape a New York rhinoplasty quotation—and the questions a complete quote should answer. Cost guide Tal Dagan, MD, FACS https://myfacesurgeon.com/guides/cost-of-botox-nyc https://myfacesurgeon.com/guides/cost-of-botox-nyc Fri, 24 Jul 2026 12:00:00 GMT What makes a New York neuromodulator quotation meaningful, including product identity, treatment map, maintenance and the difference between BOTOX® Cosmetic and DAXXIFY®. Cost guide Tal Dagan, MD, FACS https://myfacesurgeon.com/guides/facelift-recovery-time https://myfacesurgeon.com/guides/facelift-recovery-time Fri, 24 Jul 2026 12:00:00 GMT A conservative week-by-week framework for understanding early swelling, bruising, sensation, firmness, scar maturation and the questions to personalize before a seamless facelift. Recovery guide Tal Dagan, MD, FACS https://myfacesurgeon.com/guides/rhinoplasty-recovery-time https://myfacesurgeon.com/guides/rhinoplasty-recovery-time Fri, 24 Jul 2026 12:00:00 GMT A conservative week-by-week account of splint care, congestion, bruising, swelling, activity restrictions, airway healing and the long refinement period after rhinoplasty. Recovery guide Tal Dagan, MD, FACS https://myfacesurgeon.com/guides/eyelid-lift-recovery-time https://myfacesurgeon.com/guides/eyelid-lift-recovery-time Fri, 24 Jul 2026 12:00:00 GMT A week-by-week framework for bruising, swelling, prescribed eye care, dryness, light sensitivity, incision maturation and functional monitoring after blepharoplasty. Recovery guide Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/picosecond-laser-skincare-photoaging-2026 https://myfacesurgeon.com/trends/picosecond-laser-skincare-photoaging-2026 Thu, 23 Jul 2026 12:00:00 GMT In a randomized evaluator-blinded split-face study published July 23, 2026, a 755-nm picosecond alexandrite laser improved photoaging measures, and the side assigned to a branded adjunct skincare regimen showed greater wrinkle and texture gains. It is useful signal-level evidence for peri-procedure skin support, but the single-center design, photoaging focus and company-linked regimen mean clinicians should avoid treating one post-laser routine as universally superior. picosecond laser Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/low-cross-linked-ha-skin-quality-2026 https://myfacesurgeon.com/trends/low-cross-linked-ha-skin-quality-2026 Thu, 23 Jul 2026 12:00:00 GMT A 25-patient observational study published July 23, 2026 reported improved periorbital and perioral wrinkle scores, skin-quality measures and ultrasound-based dermal findings after three sessions of low-cross-linked hyaluronic-acid microinjections. The early signal is interesting for thin, mobile facial areas, but the cohort was small, non-comparative and included industry involvement, so it should not be read as a blanket answer for every fine-line concern. low-cross-linked hyaluronic acid Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/ev-facial-rejuvenation-review-2026 https://myfacesurgeon.com/trends/ev-facial-rejuvenation-review-2026 Wed, 22 Jul 2026 12:00:00 GMT A systematic review published July 22, 2026 found preliminary signals that extracellular-vesicle therapies may improve wrinkle severity, pigmentation, hydration, elasticity or overall appearance in nonsurgical facial rejuvenation studies. The same review rated the evidence low to very low certainty and noted moderate-to-critical risk of bias, so this remains an emerging regenerative area that needs stronger trials before confident mainstream use. extracellular vesicles Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/txa-rhinoplasty-recovery-2026 https://myfacesurgeon.com/trends/txa-rhinoplasty-recovery-2026 Wed, 15 Jul 2026 12:00:00 GMT In a triple-blind randomized trial of 75 primary open rhinoplasty patients, both topical and injected tranexamic acid outperformed saline for early periorbital edema and ecchymosis, with the topical route performing best through day 3. It is promising postoperative-support data, not a universal recovery instruction, and surgeons still individualize bleeding and clotting precautions. tranexamic acid Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/alloclae-adipose-allograft-2026 https://myfacesurgeon.com/trends/alloclae-adipose-allograft-2026 Tue, 14 Jul 2026 12:00:00 GMT alloClae is a ready-to-use human adipose-tissue allograft intended for localized subcutaneous cushioning and support where fat naturally exists. It avoids a fat-harvest procedure, but it is not a synthetic facial filler, does not contain living cells, and carries tissue-product risks that deserve a careful candidacy and consent discussion. alloClae Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/belotero-intense-lips-fda-2026 https://myfacesurgeon.com/trends/belotero-intense-lips-fda-2026 Thu, 09 Jul 2026 12:00:00 GMT The FDA approved Belotero Intense (+) Lidocaine on July 9, 2026 for submucosal and/or subcutaneous implantation for lip augmentation in adults over 21. Approval confirms an authorized indication and labeling pathway, not that one filler is best for every lip shape, anatomy or risk profile. Belotero Intense Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/botulinum-toxin-scar-prevention-2026 https://myfacesurgeon.com/trends/botulinum-toxin-scar-prevention-2026 Wed, 01 Jul 2026 12:00:00 GMT A 2026 systematic review and meta-analysis pooled 19 studies involving 686 patients and found better scar scores, narrower scars and higher satisfaction with botulinum toxin type A, while also calling for larger, more uniform trials. That makes it an evidence-building option for selected fresh scars rather than a blanket recommendation for every incision. botulinum toxin Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/combined-facial-rejuvenation-2026 https://myfacesurgeon.com/trends/combined-facial-rejuvenation-2026 Wed, 24 Jun 2026 12:00:00 GMT The American Society of Plastic Surgeons reported on research pairing face and neck lift surgery with plasma skin resurfacing. The report also emphasizes that further study is needed before broad conclusions are drawn. facelift Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/rfmn-vs-co2-acne-scars-2026 https://myfacesurgeon.com/trends/rfmn-vs-co2-acne-scars-2026 Thu, 18 Jun 2026 12:00:00 GMT In a randomized split-face trial, radiofrequency microneedling and fractional CO2 laser both improved facial atrophic acne scars, but microneedling radiofrequency was linked to shorter redness, pain, swelling and scab-detachment time and fewer post-inflammatory hyperpigmentation events. Treatment choice still depends on scar type, skin tone, downtime tolerance and physician technique. acne scars Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/skinvive-neck-lines-2026 https://myfacesurgeon.com/trends/skinvive-neck-lines-2026 Thu, 11 Jun 2026 12:00:00 GMT A June 2026 FDA supplement describes SKINVIVE by JUVEDERM for cheek smoothness and for reducing neck lines in adults over 21. Approval language does not replace an individual medical evaluation. SKINVIVE Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/autologous-fibroblast-rejuvenation-2026 https://myfacesurgeon.com/trends/autologous-fibroblast-rejuvenation-2026 Mon, 01 Jun 2026 12:00:00 GMT A randomized open-label controlled study of 40 patients reported greater 12-month gains in wrinkle scores and skin elasticity with autologous fibroblast micrografts than with a hyaluronic-acid skin booster, with only mild short-lived swelling and redness reported in both groups. The study is intriguing but still small, open-label and technique-dependent, so broader replication matters before this becomes mainstream planning. autologous fibroblasts Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/facelift-restraint-newbeauty-2026 https://myfacesurgeon.com/trends/facelift-restraint-newbeauty-2026 Fri, 17 Apr 2026 12:00:00 GMT A recent NewBeauty feature describes a shift toward deeper structural repositioning, restraint and results that do not advertise the operation. It is an editorial perspective-not a universal technique rule-but it closely mirrors the question patients should ask: will the plan restore support while preserving expression and identity? modern facelift Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/natural-facial-plastic-surgery-trends-2026 https://myfacesurgeon.com/trends/natural-facial-plastic-surgery-trends-2026 Tue, 24 Feb 2026 12:00:00 GMT AAFPRS survey reporting points toward earlier, subtler and more strategic treatment requests, with emphasis on facial identity, preservation and long-term skin health rather than visibly overdone change. natural results Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/biocorneum-bruise-system-2026 https://myfacesurgeon.com/trends/biocorneum-bruise-system-2026 Wed, 14 Jan 2026 12:00:00 GMT BIOCORNEUM announced a two-product system marketed for use around cosmetic and surgical procedures. Claims in a company announcement require independent evaluation; patients should confirm every topical product with their treating clinician. bruise care Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/post-procedure-products-2026 https://myfacesurgeon.com/trends/post-procedure-products-2026 Thu, 01 Jan 2026 12:00:00 GMT NewBeauty's 2026 post-procedure selections highlight products positioned for bruising, barrier support, gentle cleansing and scar care. Product awards are editorial-not medical endorsements-and postoperative instructions from your clinician come first. post procedure skin care Tal Dagan, MD, FACS https://myfacesurgeon.com/trends/regenerative-aesthetics-2026 https://myfacesurgeon.com/trends/regenerative-aesthetics-2026 Mon, 29 Dec 2025 12:00:00 GMT ASPS contributors identify regenerative approaches, earlier facial procedures and laser resurfacing among the themes shaping 2026. These are trends-not proof that every featured option is appropriate for every patient. regenerative aesthetics Tal Dagan, MD, FACS